Analysts Are Bullish on Top Healthcare Stocks: Tetraphase (TTPH), Axsome Therapeutics Inc (AXSM)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tetraphase (TTPH) and Axsome Therapeutics Inc (AXSM) with bullish sentiments.

Tetraphase (TTPH)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Tetraphase today and set a price target of $7. The company’s shares closed yesterday at $1.30, close to its 52-week low of $1.01.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 9.5% and a 41.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.

Currently, the analyst consensus on Tetraphase is a Moderate Buy with an average price target of $3.

See today’s analyst top recommended stocks >>

Axsome Therapeutics Inc (AXSM)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics Inc, with a price target of $18. The company’s shares closed yesterday at $10.71, close to its 52-week high of $10.89.

Selvaraju said:

“We utilize a risk-adjusted net present value (rNPV) approach to assessing Axsome shares. We apply a 20% discount rate to all future cash flows along with a 28.1% effective tax rate and 33% sales and marketing rate. Our approach yields a total firm value of roughly $735M, or a price per share of roughly $18 given about 40M fully-diluted shares outstanding as of end-2019, which includes the exercise of 4.8M options and warrants.”

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -5.2% and a 37.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Axsome Therapeutics Inc is a Strong Buy with an average price target of $18, representing a 68.1% upside. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $16 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts